• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cingulate Inc. - Common Stock (NQ:CING)

5.940 -0.260 (-4.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cingulate Inc. - Common Stock

News headline image
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
April 06, 2026
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate... 
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
November 18, 2025
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate... 
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
August 21, 2025
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate... 
Via Newsfile
News headline image
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
June 18, 2025
Dallas, Texas--(Newsfile Corp. - June 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital... 
Via Newsfile
News headline image
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023
Data Accepted as Finalist for First Annual Poster Awards 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Present at 13th Annual LD Micro Invitational
May 25, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023
From Indegene Inc
Via GlobeNewswire
Cingulate Inc. (NASDAQ: CING) Featured in Coverage of the 35th Annual Roth Conference
February 28, 2023
Via Investor Brand Network
News headline image
Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING)
December 10, 2021
NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ:CING).... 
From Aegis Capital Corp.
Via AccessWire
Topics Retirement
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap